AI assistant
BeOne Medicines Ltd. — Director's Dealing 2024
Jun 7, 2024
30073_dirs_2024-06-07_740635be-13f4-45f2-85f3-3a16422e037c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2024-06-05
Reporting Person: Wang Julia Aijun (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-05 | Ordinary Shares | A | 136240 | — | Acquired | 456326 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-05 | Share Option (Right to Buy) | $12.23 | A | 256659 | Acquired | 2034-06-04 | Ordinary Shares (256659) | Direct |
Footnotes
F1: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F2: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
F3: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.